Nanotechnology for the treatment of melanoma skin cancer. Naves, L. B., Dhand, C., Venugopal, J. R., Rajamani, L., Ramakrishna, S., & Almeida, L. Progress in Biomaterials, 6(1-2):13–26, May, 2017. Publisher: Springer Naturedoi abstract bibtex Melanoma is the most aggressive type of skin cancer and has very high rates of mortality. An early stage melanoma can be surgically removed, with a survival rate of 99%. This literature review intends to elucidate the possibilities to treat melanoma skin cancer using hybrid nanofibers developed by advanced electrospinning process. In this review we have shown that the enhanced permeability and retention is the basis for using nanotechnology, aiming topical drug delivery. The importance of the detection of skin cancer in the early stages is directly related to non-metastatic effects and survival rates of melanoma cells. Inhibitors of protein kinase are already available in the market for melanoma treatment and are approved by the FDA; these agents are cobimetinib, dabrafenib, ipilimumab, nivolumab, trametinib, and vemurafenib. We also report a case study involving two different approaches for targeting melanoma skin cancer therapy, namely, magnetic-based core-shell particles and electrospun mats.
@article{naves_nanotechnology_2017,
title = {Nanotechnology for the treatment of melanoma skin cancer},
volume = {6},
issn = {2194-0509},
doi = {10.1007/s40204-017-0064-z},
abstract = {Melanoma is the most aggressive type of skin cancer and has very high rates of mortality. An early stage melanoma can be surgically removed, with a survival rate of 99\%. This literature review intends to elucidate the possibilities to treat melanoma skin cancer using hybrid nanofibers developed by advanced electrospinning process. In this review we have shown that the enhanced permeability and retention is the basis for using nanotechnology, aiming topical drug delivery. The importance of the detection of skin cancer in the early stages is directly related to non-metastatic effects and survival rates of melanoma cells. Inhibitors of protein kinase are already available in the market for melanoma treatment and are approved by the FDA; these agents are cobimetinib, dabrafenib, ipilimumab, nivolumab, trametinib, and vemurafenib. We also report a case study involving two different approaches for targeting melanoma skin cancer therapy, namely, magnetic-based core-shell particles and electrospun mats.},
number = {1-2},
urldate = {2020-01-19},
journal = {Progress in Biomaterials},
author = {Naves, Lucas B. and Dhand, Chetna and Venugopal, Jayarama Reddy and Rajamani, Lakshminarayanan and Ramakrishna, Seeram and Almeida, Luis},
month = may,
year = {2017},
note = {Publisher: Springer Nature},
pages = {13--26},
}
Downloads: 0
{"_id":"nZWCou5mqqCTk6A9B","bibbaseid":"naves-dhand-venugopal-rajamani-ramakrishna-almeida-nanotechnologyforthetreatmentofmelanomaskincancer-2017","author_short":["Naves, L. B.","Dhand, C.","Venugopal, J. R.","Rajamani, L.","Ramakrishna, S.","Almeida, L."],"bibdata":{"bibtype":"article","type":"article","title":"Nanotechnology for the treatment of melanoma skin cancer","volume":"6","issn":"2194-0509","doi":"10.1007/s40204-017-0064-z","abstract":"Melanoma is the most aggressive type of skin cancer and has very high rates of mortality. An early stage melanoma can be surgically removed, with a survival rate of 99%. This literature review intends to elucidate the possibilities to treat melanoma skin cancer using hybrid nanofibers developed by advanced electrospinning process. In this review we have shown that the enhanced permeability and retention is the basis for using nanotechnology, aiming topical drug delivery. The importance of the detection of skin cancer in the early stages is directly related to non-metastatic effects and survival rates of melanoma cells. Inhibitors of protein kinase are already available in the market for melanoma treatment and are approved by the FDA; these agents are cobimetinib, dabrafenib, ipilimumab, nivolumab, trametinib, and vemurafenib. We also report a case study involving two different approaches for targeting melanoma skin cancer therapy, namely, magnetic-based core-shell particles and electrospun mats.","number":"1-2","urldate":"2020-01-19","journal":"Progress in Biomaterials","author":[{"propositions":[],"lastnames":["Naves"],"firstnames":["Lucas","B."],"suffixes":[]},{"propositions":[],"lastnames":["Dhand"],"firstnames":["Chetna"],"suffixes":[]},{"propositions":[],"lastnames":["Venugopal"],"firstnames":["Jayarama","Reddy"],"suffixes":[]},{"propositions":[],"lastnames":["Rajamani"],"firstnames":["Lakshminarayanan"],"suffixes":[]},{"propositions":[],"lastnames":["Ramakrishna"],"firstnames":["Seeram"],"suffixes":[]},{"propositions":[],"lastnames":["Almeida"],"firstnames":["Luis"],"suffixes":[]}],"month":"May","year":"2017","note":"Publisher: Springer Nature","pages":"13–26","bibtex":"@article{naves_nanotechnology_2017,\n\ttitle = {Nanotechnology for the treatment of melanoma skin cancer},\n\tvolume = {6},\n\tissn = {2194-0509},\n\tdoi = {10.1007/s40204-017-0064-z},\n\tabstract = {Melanoma is the most aggressive type of skin cancer and has very high rates of mortality. An early stage melanoma can be surgically removed, with a survival rate of 99\\%. This literature review intends to elucidate the possibilities to treat melanoma skin cancer using hybrid nanofibers developed by advanced electrospinning process. In this review we have shown that the enhanced permeability and retention is the basis for using nanotechnology, aiming topical drug delivery. The importance of the detection of skin cancer in the early stages is directly related to non-metastatic effects and survival rates of melanoma cells. Inhibitors of protein kinase are already available in the market for melanoma treatment and are approved by the FDA; these agents are cobimetinib, dabrafenib, ipilimumab, nivolumab, trametinib, and vemurafenib. We also report a case study involving two different approaches for targeting melanoma skin cancer therapy, namely, magnetic-based core-shell particles and electrospun mats.},\n\tnumber = {1-2},\n\turldate = {2020-01-19},\n\tjournal = {Progress in Biomaterials},\n\tauthor = {Naves, Lucas B. and Dhand, Chetna and Venugopal, Jayarama Reddy and Rajamani, Lakshminarayanan and Ramakrishna, Seeram and Almeida, Luis},\n\tmonth = may,\n\tyear = {2017},\n\tnote = {Publisher: Springer Nature},\n\tpages = {13--26},\n}\n\n","author_short":["Naves, L. B.","Dhand, C.","Venugopal, J. R.","Rajamani, L.","Ramakrishna, S.","Almeida, L."],"key":"naves_nanotechnology_2017","id":"naves_nanotechnology_2017","bibbaseid":"naves-dhand-venugopal-rajamani-ramakrishna-almeida-nanotechnologyforthetreatmentofmelanomaskincancer-2017","role":"author","urls":{},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/davidrpoa","dataSources":["fvS7tt2THEKMbWDXR"],"keywords":[],"search_terms":["nanotechnology","treatment","melanoma","skin","cancer","naves","dhand","venugopal","rajamani","ramakrishna","almeida"],"title":"Nanotechnology for the treatment of melanoma skin cancer","year":2017}